Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies

被引：11

作者：

Balaian, L

Ball, ED

机构：

[1] Univ Calif San Diego, Blood & Marrow Transplantat Div, La Jolla, CA 92093 USA

[2] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA

[3] Univ Calif San Diego, Sch Med, Canc Ctr, La Jolla, CA 92093 USA

来源：

LEUKEMIA RESEARCH | 2004年 / 28卷 / 08期

关键词：

myeloid leukemia; bispecific antibodies; CD33; receptor;

D O I：

10.1016/j.leukres.2003.12.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bi-specific anti-CD33 x anti-CD64 antibodies (BsAb) mediated more potent and longer-lasting inhibition of proliferation of human leukemia cell lines and primary acute myeloid leukemia (AML) samples compared to mono-specific anti-CD33 mAb. There were no differences between these two antibodies in cellular internalization over time. The inhibitory effect of BsAb was mimicked by a mouse IgG2a subclass mono-specific anti-CD33 mAb. These findings indicate that enhanced inhibition of proliferation was caused by simultaneous ligation of both CD33 and CD64 molecules. We conclude that inhibition of leukemia cell growth initiated by BsAb during prolonged exposure may have therapeutic value for the treatment of AML. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：821 / 829

页数：9

共 30 条

[1]

APPLEBAUM F, 1999, SEMIN HEMATOL S6, V36, P2

[2] The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression [J].